Cathie Wood’s ARK Invest’s largest purchase by value during July 13-17 was Elon Musk’s Space Exploration Technologies (SPCX), ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving -3.13% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%. On ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and ...

That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...